Atopic Dermatitis/Atopic Eczema | Current Treatment: Physician Insights | US | 2018
Topical corticosteroids, topical calcineurin inhibitors, and systemic immunosuppressants have historically served as the backbone of atopic dermatitis (AD) treatment. Last year, two new options entered the U.S. AD armamentarium: Pfizer’s Eucrisa, a novel nonsteroidal topical therapy for mild to moderate AD, and Sanofi/Regeneron’s Dupixent, the first targeted biological therapy approved for AD, which provides physicians with a much-needed alternative to cyclosporine and other systemic immunosuppressants in topical-refractory moderate to severe patients. The U.S. Current Treatment: Physician Insights in Atopic Dermatitis is a primary market research-based report exploring current physician prescribing practices, the impact of the new brands, factors that drive physicians’ use of key therapies, and anticipated changes in prescribing in the coming year.
Questions Answered
- How do dermatologists and pediatricians differ in their management of AD?
- At which line of therapy is Dupixent seeing use?
- Which drugs are the patient share leaders in AD? How are key nonsteroidal agents positioned in surveyed physicians’ treatment algorithms?
- What are the most influential drivers of treatment selection in AD?
- What are the common treatment scenarios preceding initiation of nonsteroidal therapies including Dupixent, Eucrisa, and topical calcineurin inhibitors?
- What factors drive movement of AD patients through lines of therapy?
Product Description
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so you can create specific messaging around these treatment dynamics in order to more effectively increase or defend your market position.
